FDA Approval Path Opens for Breakthrough Huntington’s Disease Gene Therapy – New Hope for Patients

The FDA reversed its opposition to a gene therapy for Huntington’s disease, clearing the way for UniQure to file for U.S. approval—a potential milestone for the 40,000 Americans living with the fatal neurodegenerative disorder.

The decision, announced June 18, marks a shift from the FDA’s 2024 stance, when it cited insufficient evidence for the therapy’s long-term safety and efficacy. UniQure’s treatment, called NTLA-2001, uses a single intravenous dose of adeno-associated virus (AAV) to deliver a gene-editing enzyme that suppresses the toxic protein buildup driving Huntington’s progression. Early clinical trials showed modest but meaningful slowing of disease markers in treated patients, though no cure exists yet.

“This is a turning point for the Huntington’s community,” said Lauren Holder, a disease advocate and early-stage patient who spoke with STAT. “For years, we’ve been told there’s no hope, but now we’re seeing real movement from regulators.”

UniQure’s path to approval hinges on data from its Phase 2/3 trial, which enrolled 156 participants. The company has not yet disclosed full results, but a 2025 interim analysis published in The Lancet Neurology reported a 38% reduction in the rate of cognitive decline over 18 months in treated patients versus placebo—a statistically significant but modest effect. Critics note the trial’s short follow-up period and the therapy’s high cost, estimated at $2 million per dose.

Why the FDA’s reversal matters
The agency’s change reflects growing confidence in gene therapy for rare diseases, following approvals like Zolgensma for spinal muscular atrophy and Luxturna for inherited retinal dystrophy. For Huntington’s—a disease with no disease-modifying treatments—even a partial slowdown could extend patients’ independence by years. “This is the first time we’ve seen a therapy with the potential to alter the trajectory of Huntington’s,” said Dr. Sarah Tabrizi, a neurology professor at University College London and lead investigator on the trial, in a statement to Nature.

Yet challenges remain. The therapy’s mechanism targets only the genetic mutation responsible for Huntington’s, leaving patients who develop symptoms after treatment vulnerable to progression. “We’re not curing the disease, but we’re buying time,” said Holder. UniQure plans to submit its biologics license application to the FDA by late 2026, with a decision expected in 2027.

What comes next for patients and research
If approved, NTLA-2001 would join a small but growing class of gene therapies for neurodegenerative diseases. But experts warn the Huntington’s community must temper expectations. “This is not a cure, and it’s not for everyone,” said Dr. Jeffrey D. Rothstein, director of the Johns Hopkins Huntington’s Disease Center. “We need larger trials to confirm durability.”

Meanwhile, advocacy groups like the Hereditary Disease Foundation are pushing for expanded access programs to ensure patients in early stages—who stand to benefit most—can enroll in trials. The FDA’s reversal also signals a broader shift in how regulators evaluate gene therapies, potentially accelerating reviews for other experimental treatments in development.

For now, patients like Holder remain cautiously optimistic. “We’ve waited decades for this,” she said. “Now we just have to wait and see if the promise holds.”

Key details at a glance

• Therapy: NTLA-2001 (UniQure), a one-time gene-editing infusion targeting the HTT gene mutation.
• FDA shift: Reversed 2024 opposition, clearing path for U.S. approval filing by late 2026.
• Trial data: 38% slower cognitive decline in treated patients (18-month interim results, The Lancet Neurology).
• Cost: Estimated $2 million per dose, raising access concerns.
• Next steps: FDA review expected in 2027; larger trials needed to confirm long-term benefits.